AHA/ASA Journals

Bleeding Risk With Apixaban Versus Rivaroxaban: A Reference Trial Emulation Predicting the Results of COBRRA-VTE and COBRRA-AF Using US Health Care Claims

BACKGROUND: Direct oral anticoagulants such as apixaban and rivaroxaban, have transformed the management of thromboembolic ...
The New England Journal of Medicine

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...
TCTMD

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

Patients treated with apixaban (Eliquis; Bristol Myers Squibb) for 3 months after acute venous thromboembolism (VTE) report more than half the rate of clinically relevant bleeding compared with those ...
Healio

TRACK trial: Low-dose rivaroxaban fails to reduce CV risks for patients with advanced CKD

Treatment with low-dose rivaroxaban did not reduce risks for adverse CV events and increased risks for major bleeding among ...
EurekAlert!

Safer blood clot treatment with apixaban than with rivaroxaban, according to large venous thrombosis trial

An international clinical trial led by Dr. Lana Castellucci of The Ottawa Hospital and the University of Ottawa shows that apixaban is safer than rivaroxaban for treating venous thrombosis. The first ...
Healio

Bleeding risk lower with apixaban vs. rivaroxaban for venous thromboembolism

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with apixaban was tied to lower bleeding risk vs. rivaroxaban. Adherence to ...